LY-2584702 (hydrochloride) manufacturers
|
| | LY-2584702 (hydrochloride) Basic information |
| Product Name: | LY-2584702 (hydrochloride) | | Synonyms: | LY-2584702 (hydrochloride);4-[4-[4-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-methyl-1H-imidazol-2-yl]-1-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride (1:1);LY2584702 HCl;LY-2584702 hydrochloride
(LY2584702);LY 2584702 hydrochloride,LY2584702 hydrochloride | | CAS: | 1082948-81-9 | | MF: | C21H20ClF4N7 | | MW: | 481.88 | | EINECS: | | | Product Categories: | | | Mol File: | 1082948-81-9.mol |  |
| | LY-2584702 (hydrochloride) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | LY-2584702 (hydrochloride) Usage And Synthesis |
| Uses | LY-2584702 hydrochloride is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM. | | in vivo | LY-2584702 demonstrates significant single-agent efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models at two dose levels of 2.5 mg/kg twice daily (BID) and 12.5 mg/kg BID. LY-2584702 demonstrates statistically significant tumour growth reduction at TMED50 (threshold minimum effective dose 50%) (2.3 mg/kg) and TMED90 (10 mg/kg) in the HCT116 colon carcinoma xenograft model[1]. To examine the role of S6K in vivo, EOMA cells expressing shAkt3 are implanted in nu/nu mice, then treated for 14 days with LY-2584702 or Rapamycin. Analysis of tumors removed after 14 days shows that LY-2584702 inhibits S6 phosphorylation almost as effectively as Rapamycin. Loss of Akt3 increases tumor growth as compared with pLKO. LY-2584702 treatment alone does not significantly affect the growth of pLKO tumors. However, LY-2584702 significantly reduces the growth of tumors with shAkt3[2]. | | IC 50 | p70S6K: 4 nM (IC50) | | References | [1] Tolcher A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumors. Eur J Cancer. 2014 Mar;50(5):867-75. DOI:10.1016/j.ejca.2013.11.039
[2] Phung TL, et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015 Jan 1;75(1):40-50. DOI:10.1158/0008-5472.CAN-13-2961
[3] Chen B, et al. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS One. 2017 Aug 9;12(8):e0182891. DOI:10.1371/journal.pone.0182891 |
| | LY-2584702 (hydrochloride) Preparation Products And Raw materials |
|